Scientech Research LLC Invests $1.84 Million in Repligen Corporation $RGEN

Key Points

• Scientech Research LLC has made a new investment in Repligen Corporation, acquiring 14,437 shares valued at approximately $1,837,000, making it 18th in their investment portfolio.
• Repligen reported a revenue increase of 14.8% year-over-year, with quarterly earnings of $0.37 EPS, missing estimates by $0.03.
• Wall Street analysts have a consensus price target of $169.55 for Repligen, with ratings ranging from "buy" to "hold" among eight analysts.

Scientech Research LLC acquired a new position in Repligen Corporation (NASDAQ:RGEN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 14,437 shares of the biotechnology company's stock, valued at approximately $1,837,000. Repligen comprises about 0.5% of Scientech Research LLC's investment portfolio, making the stock its 18th largest position.

Several other hedge funds have also recently made changes to their positions in RGEN. Raiffeisen Bank International AG purchased a new position in Repligen in the 4th quarter worth $29,000. Twin Tree Management LP purchased a new stake in shares of Repligen during the first quarter valued at approximately $29,000. Signaturefd LLC increased its stake in shares of Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after buying an additional 128 shares during the period. Center for Financial Planning Inc. raised its holdings in Repligen by 110.3% during the 1st quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company's stock valued at $47,000 after buying an additional 193 shares during the last quarter. Finally, UMB Bank n.a. boosted its position in Repligen by 99.4% during the 1st quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company's stock valued at $85,000 after buying an additional 332 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Jefferies Financial Group lowered their price objective on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a research note on Friday. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research report on Wednesday, July 30th. Evercore ISI reduced their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a report on Wednesday, September 3rd. Finally, Royal Bank Of Canada reiterated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a report on Tuesday, September 2nd. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $166.67.

Repligen Stock Down 3.2%

Shares of NASDAQ RGEN traded down $3.83 during trading on Friday, reaching $115.69. The company had a trading volume of 245,066 shares, compared to its average volume of 771,608. Repligen Corporation has a 12-month low of $102.96 and a 12-month high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The business's 50-day moving average is $121.01 and its 200 day moving average is $128.35. The stock has a market cap of $6.51 billion, a PE ratio of -462.66, a P/E/G ratio of 2.21 and a beta of 1.07.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business's revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.40 EPS. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus acquired 1,800 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.